| 24A652 |
Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al. |
Federal Circuit |
2024-12-31 |
Presumed Complete |
|
generic-drug hatch-waxman-act induced-infringement patent-infringement section-viii skinny-label |
Question not identified. |
| 23-1320 |
GlaxoSmithKline, LLC, et al. v. Superior Court of California, Alameda County |
California |
2024-06-18 |
Denied |
Amici (1) |
can the consumer's home state assert specific per brand-name-manufacturer due-process generic-drug generic-drugs innovator-liability personal-jurisdiction preemption product-liability specific-jurisdiction warning-label-liability |
When a plaintiff alleges injury from the consumption of a generic drug, can the consumer's home state assert specific personal jurisdiction over an ou… |
| 22-37 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-07-13 |
Denied |
CVSGAmici (5)Relisted (3) |
active-inducement fda-approval generic-drug generic-drugs hatch-waxman-act inducement-doctrine patent-infringement skinny-label |
If a generic drug's FDA-approved label carves out all of the language that the brand manufacturer has identified as covering its patented uses, can th… |
| 20-1572 |
Ramon D. Johnson, II v. Novartis Pharmaceuticals Corporation, et al. |
Fifth Circuit |
2021-05-13 |
Denied |
Response WaivedRelisted (2) |
brand-name-liability brand-name-manufacturer FDA-approval generic-drug generic-drug-liability label-defect leave-to-amend preemption product-liability state-law-claims texas-presumption-of-no-liability unapproved-indication |
In Pliva, Inc. v. Mensing 564 U.S. 604 (2011)
the only question before this Court was whether a
state law duty for a generic drug manufacturer to
p… |